CAH:NYSECardinal Health, Inc. Analysis

Cardinal Health posted a solid top‑line beat, with revenue climbing 11% YoY to $250.7 B and operating earnings rising 29% to $707 M, while non‑GAAP EPS surged 19% to $1.97, comfortably exceeding analyst expectations. At a market price of $200.68, the stock trades well below the DCF‑derived fair value of $406.74, implying a potential upside of over 22% and positioning the company as undervalued despite a trailing P/E of ~30 versus the industry average of 27.6. The dividend remains modest at 1.02% with a payout ratio around 31%, supported by robust operating cash flow exceeding $5 B, suggesting sustainability.
Technical indicators are mixed but lean bullish: the MACD histogram is positive, the signal line turned bullish, and RSI sits at a neutral 53, while price sits comfortably above the 20‑day SMA (194.75) and below the 50‑day SMA (204.41), indicating room for further upside toward the $206.6 resistance. Volatility is elevated at ~31% over 30 days, yet beta is essentially neutral, and the company’s exposure is largely domestic, limiting currency and geographic risk. Combined with a strong analyst consensus of “strong buy,” the fundamentals, valuation gap, and dividend profile support a positive outlook.